Related Experiment Video

Updated: Jul 17, 2026

Generation of Monoclonal Antibodies Against Natural Products
12:15

Generation of Monoclonal Antibodies Against Natural Products

Published on: April 6, 2019

Molecular characterisation of canine nonsteroidal anti-inflammatory drug-activated gene (NAG-1)

Kiyoshi Yamaguchi1, Nichelle C Whitlock, Jason L Liggett

  • 1Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37996, USA.

Veterinary Journal (London, England : 1997)
|February 6, 2007
PubMed

Insights

Canine nonsteroidal anti-inflammatory drug (NSAID)-activated gene (NAG-1) was identified and studied in osteosarcoma cells. Certain anti-cancer drugs, including NSAIDs and PPARgamma ligands, effectively increased canine NAG-1 expression.

Area of Science:

  • Molecular biology
  • Genomics
  • Cancer research

Background:

  • Nonsteroidal anti-inflammatory drug (NSAID)-activated gene (NAG-1) is a TGF-β superfamily member.
  • NAG-1 is induced by anti-tumorigenic compounds like NSAIDs and PPARgamma ligands in humans.
  • Canine osteosarcoma is a prevalent and aggressive bone cancer in dogs.

Purpose of the Study:

  • To characterize canine NAG-1 from a genomic database.
  • To investigate the induction of canine NAG-1 by NSAIDs and PPARgamma ligands in canine osteosarcoma cell lines.
  • To explore canine NAG-1 as a potential therapeutic target for canine cancer.

Main Methods:

  • Canine NAG-1 gene was identified and characterized using canine genomic database.
  • Phylogenetic analysis was performed to compare canine NAG-1 with homologous genes in other species.
  • Canine osteosarcoma cell lines were treated with specific NSAIDs (piroxicam, SC-560) and a PPARgamma ligand (rosiglitazone) to assess NAG-1 gene expression.

Main Results:

  • Canine NAG-1 was successfully characterized and found to be homologous to mouse and rat NAG-1.
  • Treatment with piroxicam, SC-560, and rosiglitazone significantly increased canine NAG-1 expression in osteosarcoma cell lines.
  • These findings indicate that canine NAG-1 is up-regulated by specific anti-tumorigenic compounds.

Conclusions:

  • Canine NAG-1 is a valid target for chemotherapy in canine osteosarcoma.
  • The study provides a foundation for developing novel therapeutic strategies targeting NAG-1 in canine cancer.
  • Further research into the precise mechanisms of NAG-1 regulation and its role in canine osteosarcoma is warranted.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...